Christina Voelkel-Johnson

Publications

• Targeting Sphingosine Kinase Induces Apoptosis and Tumor Regression for KSHV-associated Primary Effusion Lymphoma
  Molecular Cancer Therapeutics. Oct, 2013  |   Pubmed ID: 24140934
• Inner Ear Supporting Cells Protect Hair Cells by Secreting HSP70
  The Journal of Clinical Investigation. Aug, 2013  |   Pubmed ID: 23863716
• Histone Deacetylase Inhibitors Restore Cell Surface Expression of the Coxsackie Adenovirus Receptor and Enhance CMV Promoter Activity in Castration-resistant Prostate Cancer Cells
  Prostate Cancer. 2012  |   Pubmed ID: 22288017
• TRAIL-mediated Signaling in Prostate, Bladder and Renal Cancer
  Nature Reviews. Urology. Aug, 2011  |   Pubmed ID: 21670755
• T Cells Expanded in Presence of IL-15 Exhibit Increased Antioxidant Capacity and Innate Effector Molecules
  Cytokine. Aug, 2011  |   Pubmed ID: 21602054
• Adenoviral Infectivity of Exfoliated Viable Cells in Urine: Implications for the Detection of Bladder Cancer
  BMC Cancer. 2011  |   Pubmed ID: 21569442
• Sorafenib Activates CD95 and Promotes Autophagy and Cell Death Via Src Family Kinases in Gastrointestinal Tumor Cells
  Molecular Cancer Therapeutics. Aug, 2010  |   Pubmed ID: 20682655
• Vorinostat and Sorafenib Increase CD95 Activation in Gastrointestinal Tumor Cells Through a Ca(2+)-de Novo Ceramide-PP2A-reactive Oxygen Species-dependent Signaling Pathway
  Cancer Research. Aug, 2010  |   Pubmed ID: 20631069
• 17-allylamino-17-demethoxygeldanamycin and MEK1/2 Inhibitors Kill GI Tumor Cells Via Ca2+-dependent Suppression of GRP78/BiP and Induction of Ceramide and Reactive Oxygen Species
  Molecular Cancer Therapeutics. May, 2010  |   Pubmed ID: 20442308
• Polymer-enhanced Adenoviral Transduction of CAR-negative Bladder Cancer Cells
  Molecular Pharmaceutics. Sep-Oct, 2009  |   Pubmed ID: 19655763
• Inhibition of Superoxide Generation Upon T-cell Receptor Engagement Rescues Mart-1(27-35)-reactive T Cells from Activation-induced Cell Death
  Cancer Research. Aug, 2009  |   Pubmed ID: 19638595
• Oxidative Stress Sensitizes Bladder Cancer Cells to TRAIL Mediated Apoptosis by Down-regulating Anti-apoptotic Proteins
  The Journal of Urology. Sep, 2009  |   Pubmed ID: 19625063
• Oxidative Stress and Lymphocyte Persistence: Implications in Immunotherapy
  Advances in Cancer Research. 2009  |   Pubmed ID: 19595310
• The Role of Protein Synthesis in Cell Cycling and Cancer
  Molecular Oncology. Dec, 2009  |   Pubmed ID: 19546037
• Sorafenib and Vorinostat Kill Colon Cancer Cells by CD95-dependent and -independent Mechanisms
  Molecular Pharmacology. Aug, 2009  |   Pubmed ID: 19483104
• MDA-7/IL-24-induced Cell Killing in Malignant Renal Carcinoma Cells Occurs by a Ceramide/CD95/PERK-dependent Mechanism
  Molecular Cancer Therapeutics. May, 2009  |   Pubmed ID: 19417161
• 
  Cancer Biology & Therapy. Jan, 2009  |   Pubmed ID: 19127121
• Transformation, Translation and TRAIL: an Unexpected Intersection
  Cytokine & Growth Factor Reviews. Apr, 2008  |   Pubmed ID: 18353705
• Doxorubicin Generates a Proapoptotic Phenotype by Phosphorylation of Elongation Factor 2
  Free Radical Biology & Medicine. Nov, 2007  |   Pubmed ID: 17893044
• Illuminating TRAIL Gene Therapy
  Cancer Biology & Therapy. Nov, 2006  |   Pubmed ID: 17204862
• Targeting the Short Form of CFLIP by RNA Interference is Sufficient to Enhance TRAIL Sensitivity in PC3 Prostate Carcinoma Cells
  Cancer Biology & Therapy. Dec, 2006  |   Pubmed ID: 17106251
• Resistance to TRAIL is Associated with Defects in Ceramide Signaling That Can Be Overcome by Exogenous C6-ceramide Without Requiring Down-regulation of Cellular FLICE Inhibitory Protein
  Molecular Cancer Therapeutics. Sep, 2005  |   Pubmed ID: 16170023
• Doxorubicin Increases the Effectiveness of Apo2L/TRAIL for Tumor Growth Inhibition of Prostate Cancer Xenografts
  BMC Cancer. Jan, 2005  |   Pubmed ID: 15638938
• In Vitro Efficacy of Fas Ligand Gene Therapy for the Treatment of Bladder Cancer
  Cancer Gene Therapy. Jan, 2005  |   Pubmed ID: 15514684
• Enhanced Apoptosis of Glioma Cell Lines is Achieved by Co-delivering FasL-GFP and TRAIL with a Complex Ad5 Vector
  Cancer Gene Therapy. Nov, 2003  |   Pubmed ID: 14605667
• An Antibody Against DR4 (TRAIL-R1) in Combination with Doxorubicin Selectively Kills Malignant but Not Normal Prostate Cells
  Cancer Biology & Therapy. May-Jun, 2003  |   Pubmed ID: 12878867
• Doxorubicin Pretreatment Sensitizes Prostate Cancer Cell Lines to TRAIL Induced Apoptosis Which Correlates with the Loss of C-FLIP Expression
  Cancer Biology & Therapy. Sep-Oct, 2002  |   Pubmed ID: 12496481
• Resistance of Prostate Cancer Cells to Soluble TNF-related Apoptosis-inducing Ligand (TRAIL/Apo2L) Can Be Overcome by Doxorubicin or Adenoviral Delivery of Full-length TRAIL
  Cancer Gene Therapy. Feb, 2002  |   Pubmed ID: 11857034